treatment |
|
comparator |
|
|
Gemcitabine | advanced breast cancer (metastatic), in all type of patients | vs capecitabine + docetaxel | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients Trial | Studied treatment | Control | Patients |
---|
Seidman, 2011 | | | |
|
Gemcitabine | advanced breast cancer (metastatic), in all type of patients | vs capecitabine plus docetaxel | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients Trial | Studied treatment | Control | Patients |
---|
Chan, 2009 | | | |
|
Gemcitabine | advanced breast cancer (metastatic), in all type of patients | vs docetaxel | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients Trial | Studied treatment | Control | Patients |
---|
Nielsen, 2011 | | | |
|
Gemcitabine | advanced breast cancer (metastatic), in all type of patients | vs epirubicin | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients Trial | Studied treatment | Control | Patients |
---|
Feher, 2005 | | | |
|
Gemcitabine | advanced breast cancer (metastatic), in all type of patients | vs paclitaxel + bevacizumab | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients Trial | Studied treatment | Control | Patients |
---|
Brufsky, 2011 | | | |
|
Gemcitabine | advanced breast cancer (metastatic), in all type of patients | vs paclitaxel monotherapy | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients Trial | Studied treatment | Control | Patients |
---|
Albain, 2008 | | | |
|
Gemcitabine | advanced breast cancer (metastatic), in all type of patients | vs vinorelbine monotherapy | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients Trial | Studied treatment | Control | Patients |
---|
Martín, 2007 | | | |
|
Gemcitabine | advanced breast cancer (metastatic), in all type of patients | vs weekly docetaxel | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients Trial | Studied treatment | Control | Patients |
---|
Papadimitriou, 2009 | | | |
|